Table 1. Anti-proliferative effects of MPT0E028 in the NCI-60 cell line panels.
| Panels | Cell Line | GI50 (M) | TGI (M) | LC50 (M) | Panel | Cell Line | GI50 (M) | TGI (M) | LC50 (M) |
| Leukemia | CCRF-CEM | 1.65E-7 | >1.00E-4 | >1.00E-4 | Melanoma | LOX IMVE | 2.22E-7 | 7.18E-7 | 2.88E-6 |
| HL-60 (TB) | 4.39E-7 | >1.00E-4 | >1.00E-4 | MALME-3M | 3.75E-8 | 9.07E-7 | >1.00E-4 | ||
| K-562 | 1.15E-7 | >1.00E-4 | >1.00E-4 | M14 | 1.79E-7 | 1.11E-6 | 6.45E-6 | ||
| MOLT-4 | 3.17E-7 | >1.00E-4 | >1.00E-4 | MDA-MB-435 | 1.46E-7 | 7.06E-7 | 1.13E-5 | ||
| RPMI-8226 | 8.11E-8 | >1.00E-4 | >1.00E-4 | SK-MEL-2 | 4.33E-7 | 3.89E-6 | 3.49E-5 | ||
| SR | 6.01E-8 | >1.00E-4 | >1.00E-4 | SK-MEL-28 | 4.06E-7 | 2.74E-6 | >1.00E-4 | ||
| Non-Small Cell Lung Cancer | A549/ATCC | 2.30E-7 | 1.09E-6 | 9.03E-6 | SK-MEL-5 | 1.36E-7 | 3.10E-7 | 7.05E-7 | |
| EKVX | 5.34E-7 | >1.00E-4 | >1.00E-4 | UACC-257 | 1.27E-7 | 1.65E-6 | >1.00E-4 | ||
| HOP-62 | 1.87E-7 | 1.06E-6 | 1.92E-5 | UACC-62 | 7.16E-8 | 3.39E-7 | 1.66E-6 | ||
| HOP-92 | 2.10E-7 | 8.14E-7 | 1.80E-5 | Ovarian Cancer | IGROV1 | 1.83E-7 | 5.33E-7 | 2.39E-6 | |
| NCI-H226 | 1.24E-6 | 3.88E-6 | 1.90E-5 | OVCAR-3 | 2.33E-7 | 9.33E-7 | 7.30E-6 | ||
| NCI-H23 | 1.88E-7 | 9.22E-7 | 3.84E-6 | OVCAR-4 | 5.09E-7 | 3.18E-5 | >1.00E-4 | ||
| NCI-H322M | 1.86E-7 | 1.14E-5 | >1.00E-4 | OVCAR-5 | 6.02E-8 | 3.16E-7 | 2.58E-6 | ||
| NCI-H460 | 1.44E-7 | 1.66E-6 | 2.16E-5 | OVCAR-8 | 1.21E-7 | 1.75E-6 | >1.00E-4 | ||
| NCI-H522 | 1.67E-7 | 8.45E-7 | 1.30E-5 | NCI/ADR-RES | 3.85E-8 | 2.39E-7 | >1.00E-4 | ||
| Colon Cancer | COLO 205 | 1.28E-7 | 2.64E-7 | 5.46E-7 | SK-OV-3 | 1.90E-7 | 6.01E-7 | 4.26E-6 | |
| HCC-2998 | 1.94E-7 | 5.22E-7 | 2.06E-6 | Renal Cancer | 786-0 | 3.00E-7 | 1.33E-6 | 4.02E-6 | |
| HCT-116 | 5.63E-8 | 2.04E-7 | 5.66E-7 | A498 | 2.43E-7 | 1.13E-6 | 5.13E-6 | ||
| HCT-15 | 4.30E-7 | 1.31E-5 | 9.02E-5 | ACHN | 1.67E-7 | 5.76E-7 | 4.08E-6 | ||
| HT29 | 1.18E-7 | 7.16E-7 | 6.81E-5 | CAKI-1 | 2.18E-7 | 9.59E-7 | >1.00E-4 | ||
| KM12 | 2.86E-7 | 1.49E-6 | 5.78E-6 | RXF 393 | 1.12E-7 | 3.34E-7 | 9.98E-7 | ||
| SW-620 | 1.47E-7 | 1.12E-5 | >1.00E-4 | SN12C | 4.58E-7 | 1.02E-5 | >1.00E-4 | ||
| CNS Cancer | SF-268 | 4.64E-7 | 3.40E-6 | 7.04E-5 | TK-10 | 1.03E-7 | 6.60E-7 | 3.36E-5 | |
| SF-295 | 6.03E-8 | 3.40E-7 | 2.43E-6 | UO-31 | 1.69E-7 | 1.46E-6 | 5.63E-6 | ||
| SF-539 | 2.41E-7 | 1.15E-6 | 3.39E-6 | Prostate Cancer | PC-3 | 2.40E-7 | 2.10E-5 | >1.00E-4 | |
| SNB-19 | 4.34E-7 | 1.64E-6 | 5.65E-6 | DU-145 | 1.79E-7 | 1.92E-6 | >1.00E-4 | ||
| SNB-75 | 5.91E-8 | 6.27E-6 | 3.28E-5 | Breast Cancer | MCF-7 | 2.30E-7 | 1.05E-5 | 6.27E-5 | |
| U251 | 1.99E-7 | 8.20E-7 | 3.76E-6 | MAD-MB-231/ATCC | 2.41E-7 | 8.22E-7 | 2.04E-5 | ||
| HS 578T | 2.53E-7 | 1.79E-5 | >1.00E-4 | ||||||
| BT-549 | 6.80E-7 | 5.84E-6 | >1.00E-4 | ||||||
| T-47D | 1.21E-7 | 4.45E-7 | >1.00E-4 | ||||||
| MDA-MB-468 | 1.96E-7 | 1.15E-6 | 6.31E-6 | ||||||
GI50: 50% of growth inhibition;
TGI: total growth inhibition;
LC50: 50% of lethal concentration.
M: Concentration in molar (M).